MarketPeel
Insider Trading Intelligence
Pricing
…
AS

Anand Sampath

MASI
EVP, OPS & CLINICAL RESEARCH · MASIMO CORP · CIK 0001406493
FILING MIX · LIFETIME29%/71%
BUYS
10
SELLS
24
TOTAL VALUE
$27.33M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
0
AVG SELL PX
$135.02
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 9 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Anand Sampath, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+50.00%+1.08%-0.38%+1.46%+0.56%—
14d6+50.00%+2.00%+0.75%+1.25%-1.04%—
30d6+33.33%+18.45%+0.63%+17.83%+28.73%—
60d6+0.00%+18.75%-0.61%+19.36%+23.23%—
90d6+33.33%+14.35%+6.19%+8.15%+16.61%—
180d6(3 pending)+66.67%+0.67%+19.58%-18.91%-31.21%—
1y6(3 pending)+0.00%+14.73%+36.81%-22.08%-22.44%—
2y6(3 pending)+100.00%-38.73%+27.54%-66.27%-54.30%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MASI · 0 shares · as of Jun 10, 2026
014,89729,79544,69259,589202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 10 buys / 24 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MASI
MASIMO CORP
SALE
EVP, Operations
33,901$180.00$6.10M0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
10,000$93.05$930.5K0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
5,158——0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
4,422$0.58$2.6K0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
3,855$22.47$86.6K0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
4,828——0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
10,000$89.13$891.3K0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
6,840——0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
1,820——0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Operations
7,235$46.50$336.4K0Jun 10, 2026Jun 12, 2026 ↗View →
MASI
MASIMO CORP
PURCHASEGRANT
Stock grant
6,840——6,840Mar 6, 2026Mar 10, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
196$138.09$27.1K40,909Jan 28, 2026Jan 30, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
11,924$136.56$1.63M47,665Jan 28, 2026Jan 30, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
30,000——0Jan 28, 2026Jan 30, 2026 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
30,000$37.84$1.14M59,589Jan 28, 2026Jan 30, 2026 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
6,560$137.22$900.2K41,105Jan 28, 2026Jan 30, 2026 ↗View →
MASI
MASIMO CORP
PURCHASEGRANT
Stock grant
2,637$250.73$661.2K2,637Feb 26, 2021Mar 2, 2021 ↗View →
MASI
MASIMO CORP
PURCHASEGRANT
Stock grant
14,593——29,589Feb 22, 2021Feb 24, 2021 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
2,000——2,000Jan 2, 2021Jan 6, 2021 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
2,000——15,782Jan 2, 2021Jan 6, 2021 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
786$268.38$210.9K14,996Jan 2, 2021Jan 6, 2021 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
15,000——0Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
15,000$265.58$3.98M13,782Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
15,000$31.01$465.1K28,782Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
15,000$21.77$326.6K15,204Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
15,000$265.61$3.98M13,782Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
15,000$21.77$326.6K28,782Dec 15, 2020Dec 17, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
19,796$180.00$3.56M13,782Apr 13, 2020Apr 15, 2020 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
19,796$21.77$431.0K33,578Apr 13, 2020Apr 15, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
19,796$21.77$431.0K30,204Apr 13, 2020Apr 15, 2020 ↗View →
MASI
MASIMO CORP
PURCHASEGRANT
Stock grant
4,422$179.42$793.4K4,422Mar 12, 2020Mar 16, 2020 ↗View →
MASI
MASIMO CORP
PURCHASE
EVP, Ops & Clinical Research
2,000——14,518Jan 2, 2020Jan 6, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
2,000——4,000Jan 2, 2020Jan 6, 2020 ↗View →
MASI
MASIMO CORP
SALE
EVP, Ops & Clinical Research
736$158.58$116.7K13,782Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · MASI
Loading peer insiders…
About this filer
CIK 0001406493
ROLE
EVP, Ops & Clinical Research
PRIMARY
MASI
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001406493DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback